Differing severities of acute exacerbations of idiopathic pulmonary fibrosis (IPF): insights from the INPULSIS® trials

Differing severities of acute exacerbations of idiopathic pulmonary fibrosis (IPF): insights from the INPULSIS® trials

Abstract Background Given the broad definition of an acute exacerbation of IPF, it is likely that acute exacerbations are heterogeneous in their aetiology, severity and clinical course. We used pooled data from the INPULSIS® trials of nintedanib versus placebo to investigate whether acute exacerbati...

Full description

Bibliographic Details
Main Authors: Michael Kreuter, Harald Koegler, Matthias Trampisch, Silke Geier, Luca Richeldi
Format: Article
Language:English
Published: BMC 2019-04-01
Series:Respiratory Research
Subjects:
Nintedanib
Tyrosine kinase inhibitor
Serious adverse events
Disease progression
Treatment outcome
Online Access:http://link.springer.com/article/10.1186/s12931-019-1037-7

Internet

http://link.springer.com/article/10.1186/s12931-019-1037-7

Similar Items